Ocugen (OCGN) Competitors $1.54 -0.17 (-9.65%) As of 11:08 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock OCGN vs. MRNA, PFE, ANIP, VERA, TWST, OCUL, APGE, COGT, DYN, and ABCLShould you be buying Ocugen stock or one of its competitors? The main competitors of Ocugen include Moderna (MRNA), Pfizer (PFE), ANI Pharmaceuticals (ANIP), Vera Therapeutics (VERA), Twist Bioscience (TWST), Ocular Therapeutix (OCUL), Apogee Therapeutics (APGE), Cogent Biosciences (COGT), Dyne Therapeutics (DYN), and AbCellera Biologics (ABCL). These companies are all part of the "medical" sector. Ocugen vs. Its Competitors Moderna Pfizer ANI Pharmaceuticals Vera Therapeutics Twist Bioscience Ocular Therapeutix Apogee Therapeutics Cogent Biosciences Dyne Therapeutics AbCellera Biologics Moderna (NASDAQ:MRNA) and Ocugen (NASDAQ:OCGN) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, profitability, dividends, media sentiment, valuation and risk. Which has more risk and volatility, MRNA or OCGN? Moderna has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, Ocugen has a beta of 4.2, indicating that its stock price is 320% more volatile than the S&P 500. Do institutionals and insiders believe in MRNA or OCGN? 75.3% of Moderna shares are held by institutional investors. Comparatively, 10.3% of Ocugen shares are held by institutional investors. 11.0% of Moderna shares are held by company insiders. Comparatively, 4.4% of Ocugen shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth. Is MRNA or OCGN more profitable? Moderna has a net margin of -94.31% compared to Ocugen's net margin of -1,197.71%. Moderna's return on equity of -25.96% beat Ocugen's return on equity.Company Net Margins Return on Equity Return on Assets Moderna-94.31% -25.96% -20.09% Ocugen -1,197.71%-255.25%-86.79% Do analysts recommend MRNA or OCGN? Moderna presently has a consensus target price of $41.81, indicating a potential upside of 51.91%. Ocugen has a consensus target price of $6.00, indicating a potential upside of 280.95%. Given Ocugen's stronger consensus rating and higher possible upside, analysts clearly believe Ocugen is more favorable than Moderna.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Moderna 5 Sell rating(s) 14 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.00Ocugen 1 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.50 Which has better valuation and earnings, MRNA or OCGN? Ocugen has lower revenue, but higher earnings than Moderna. Ocugen is trading at a lower price-to-earnings ratio than Moderna, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioModerna$3.06B3.52-$3.56B-$7.53-3.66Ocugen$4.75M96.84-$54.05M-$0.20-7.88 Does the media favor MRNA or OCGN? In the previous week, Moderna had 13 more articles in the media than Ocugen. MarketBeat recorded 18 mentions for Moderna and 5 mentions for Ocugen. Ocugen's average media sentiment score of 0.87 beat Moderna's score of 0.54 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Moderna 5 Very Positive mention(s) 2 Positive mention(s) 8 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ocugen 1 Very Positive mention(s) 2 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive SummaryModerna beats Ocugen on 9 of the 16 factors compared between the two stocks. Get Ocugen News Delivered to You Automatically Sign up to receive the latest news and ratings for OCGN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OCGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OCGN vs. The Competition Export to ExcelMetricOcugenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$454.53M$3.33B$6.04B$10.42BDividend YieldN/A2.31%5.73%4.78%P/E Ratio-7.7722.4886.3826.98Price / Sales96.84425.03584.02182.26Price / CashN/A44.9825.7330.17Price / Book15.7510.3412.966.65Net Income-$54.05M-$52.40M$3.31B$276.12M7 Day Performance-13.46%0.61%-0.50%-1.64%1 Month Performance47.20%13.88%8.66%5.82%1 Year Performance59.90%27.93%79.84%33.08% Ocugen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OCGNOcugen1.4693 of 5 stars$1.55-9.6%$6.00+288.3%+73.6%$451.61M$4.75M-7.7280MRNAModerna4.221 of 5 stars$27.54-3.3%$41.81+51.8%-54.0%$10.72B$3.24B-3.665,800Analyst ForecastPFEPfizer4.9527 of 5 stars$26.45-3.4%$28.41+7.4%-14.9%$150.38B$63.83B14.0781,000Positive NewsDividend AnnouncementAnalyst ForecastAnalyst RevisionANIPANI Pharmaceuticals3.7922 of 5 stars$92.06+2.7%$97.29+5.7%+57.1%$2.00B$747.40M-119.56600VERAVera Therapeutics2.3114 of 5 stars$30.94+2.7%$63.00+103.6%-29.6%$1.97BN/A-8.6440TWSTTwist Bioscience3.7442 of 5 stars$31.85+2.5%$48.90+53.5%-29.9%$1.92B$312.97M-21.97990OCULOcular Therapeutix3.8907 of 5 stars$10.97-3.9%$22.13+101.7%+20.4%$1.91B$63.72M-8.57230Insider TradeAnalyst RevisionAPGEApogee Therapeutics3.0415 of 5 stars$39.82-0.2%$92.63+132.6%-7.9%$1.84BN/A-9.6491COGTCogent Biosciences1.8781 of 5 stars$15.90+0.9%$20.00+25.8%+44.6%$1.81BN/A-8.9380High Trading VolumeDYNDyne Therapeutics3.5433 of 5 stars$12.65-3.1%$34.07+169.3%-58.3%$1.80BN/A-3.28100Analyst DowngradeABCLAbCellera Biologics2.3691 of 5 stars$5.87-0.5%$8.00+36.3%+113.5%$1.75B$28.83M-10.67500 Related Companies and Tools Related Companies Moderna Alternatives Pfizer Alternatives ANI Pharmaceuticals Alternatives Vera Therapeutics Alternatives Twist Bioscience Alternatives Ocular Therapeutix Alternatives Apogee Therapeutics Alternatives Cogent Biosciences Alternatives Dyne Therapeutics Alternatives AbCellera Biologics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OCGN) was last updated on 10/13/2025 by MarketBeat.com Staff From Our PartnersURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredCapital Gains Tax Strategies for SeniorsCapital gains taxes can take a bite out of your retirement income—unless you have a smart strategy. From holdi...SmartAsset | SponsoredBitcoin grabs headlines, but smart money likes this tokenBitcoin grabs headlines, but smart money likes this token My research team has identified the token positio...Crypto 101 Media | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | Sponsored$3,600 gold is nice ... but here’s what most gold bugs are missingGold just surged past $3,600, but Weiss Ratings expert Sean Brodrick says the real upside is in select gold st...Weiss Ratings | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocugen, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocugen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
